ADC Trials Will Reshape Personalized Cancer Treatments

The notable upward revision in Mersana Therapeutics' price target appears driven by improved net profit margin despite slightly weaker revenue growth forecasts, resulting in a new consensus analyst price target of $123.29. What's in the News Mersana Therapeutics will implement a 1-for-25 reverse stock split to comply with Nasdaq minimum bid price requirements.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased revenue growth from 8.6% to -19.6%, increased profit margin from 10.5% to 17.3%, increased future PE multiple from 148.8x to 210.4x and increased shares outstanding growth rate from 0.0% to 0.0%.